STATEMENT OF PURPOSE
RS29987 / H0004
The Idaho Board of Pharmacy administers the regulatory provisions of the state's Uniform Controlled
Substances Act. This bill mirrors the federal Drug Enforcement Administration (DEA) controlled substance
scheduling decisions for 2022, including placing synthetic opioids in Schedule I, a substance to treat insomnia
in Schedule IV and an anticonvulsant substance in Schedule V.
FISCAL NOTE
This legislation will have no impact on the state's General fund or any dedicated fund or federal fund because
adding, removing, or rescheduling products to the Controlled Substances Act does not create any new state
program and does not compel any state action.
Contact:
Representative Sue Chew
(208) 332-1000
Tim Frost
Division of Occupational and Professional Licenses
(208) 577-2491
DISCLAIMER: This statement of purpose and fiscal note are a mere attachment to this bill and prepared by a proponent
of the bill. It is neither intended as an expression of legislative intent nor intended for any use outside of the legislative
process, including judicial review (Joint Rule 18).
Statement of Purpose / Fiscal Note Bill SOP/FN INTRODUCED: 01/18/2023, 9:17 AM


Statutes affected:
Bill Text: 37-2705, 37-2711, 37-2713